CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn

Reuters

Jan 30

CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn

China Resources Pharmaceutical Group Ltd. indirectly holds approximately 30.48% of the total share capital and about 41.79% of the voting rights in CR Boya Bio-pharmaceutical, making CR Boya Bio-pharmaceutical its affiliate. CR Boya Bio-pharmaceutical is listed on the Shenzhen Stock Exchange. For the year ended 31 December 2025, CR Boya Bio-pharmaceutical expects a year-on-year increase of 10.00% to 25.00% in operating revenue, mainly due to the acquisition of Green Cross HK Holdings Limited. However, the net profit attributable to shareholders is expected to see a significant decrease, primarily due to a downturn in the hyaluronic acid market and impairments related to intangible assets and goodwill of approximately RMB300 million following the acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260130-12006126), on January 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607001542"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607001542\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607001542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607001542","market":"fut","top_or_hot":-1,"title":"CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Resources Pharmaceutical Group Ltd. indirectly holds approximately 30.48% of the total share capital and about 41.79% of the voting rights in CR Boya Bio-pharmaceutical, making CR Boya Bio-pharmaceutical its affiliate. CR Boya Bio-pharmaceutical is listed on the Shenzhen Stock Exchange. For the year ended 31 December 2025, CR Boya Bio-pharmaceutical expects a year-on-year increase of 10.00% to 25.00% in operating revenue, mainly due to the acquisition of Green Cross HK Holdings Limited. However, the net profit attributable to shareholders is expected to see a significant decrease, primarily due to a downturn in the hyaluronic acid market and impairments related to intangible assets and goodwill of approximately RMB300 million following the acquisition.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260130-12006126), on January 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-30 17:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Resources Pharmaceutical Group Ltd. indirectly holds approximately 30.48% of the total share capital and about 41.79% of the voting rights in CR Boya Bio-pharmaceutical, making CR Boya Bio-pharmaceutical its affiliate. CR Boya Bio-pharmaceutical is listed on the Shenzhen Stock Exchange. For the year ended 31 December 2025, CR Boya Bio-pharmaceutical expects a year-on-year increase of 10.00% to 25.00% in operating revenue, mainly due to the acquisition of Green Cross HK Holdings Limited. However, the net profit attributable to shareholders is expected to see a significant decrease, primarily due to a downturn in the hyaluronic acid market and impairments related to intangible assets and goodwill of approximately RMB300 million following the acquisition.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260130-12006126), on January 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1570","symbol_name":"华润系","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL2xPs21:1","article_id":"2607001542","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607001542","pubTimestamp":1769766892,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"China Resources Pharmaceutical Group Ltd. indirectly holds approximately 30.48% of the total share capital and about 41.79% of the voting rights in CR Boya Bio-pharmaceutical, making CR Boya Bio-pharmaceutical its affiliate. CR Boya Bio-pharmaceutical is listed on the Shenzhen Stock Exchange. For the year ended 31 December 2025, CR Boya Bio-pharmaceutical expects a year-on-year increase of 10.00% to 25.00% in operating revenue, mainly due to the acquisition of Green Cross HK Holdings Limited. However, the net profit attributable to shareholders is expected to see a significant decrease, primarily due to a downturn in the hyaluronic acid market and impairments related to intangible assets and goodwill of approximately RMB300 million following the acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300294":"博雅生物","BK1570":"华润系","BK0046":"生物疫苗","BK1191":"制药","03320":"华润医药","BK0197":"中小创蓝筹","BK0239":"医药制造"},"translate_title":"华润博雅生物制药附属项目净利润在市场低迷中下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300294":0.9,"03320":0.9},"content_text":"CR Boya Bio-pharmaceutical Affiliate Projects Net Profit Drop Amid Market Downturn\n    \n\n        China Resources Pharmaceutical Group Ltd. indirectly holds approximately 30.48% of the total share capital and about 41.79% of the voting rights in CR Boya Bio-pharmaceutical, making CR Boya Bio-pharmaceutical its affiliate. CR Boya Bio-pharmaceutical is listed on the Shenzhen Stock Exchange. For the year ended 31 December 2025, CR Boya Bio-pharmaceutical expects a year-on-year increase of 10.00% to 25.00% in operating revenue, mainly due to the acquisition of Green Cross HK Holdings Limited. However, the net profit attributable to shareholders is expected to see a significant decrease, primarily due to a downturn in the hyaluronic acid market and impairments related to intangible assets and goodwill of approximately RMB300 million following the acquisition.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260130-12006126), on January 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}